14-day Premium Trial Subscription Try For FreeTry Free
NYSE:BDXA
Delisted

Becton Dickinson and Co Depositary ETF News

$59.24
+0 (+0%)
At Close: Sep 04, 2020
Becton, Dickinson and Company's (BDX) CEO Tom Polen on Q4 2021 Results - Earnings Call Transcript
Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.58% and 4.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Becton Dickinson and Co (NYSE: BDX) has partnered with Amazon.com Inc (NASDAQ: AMZN) to begin shipment of a new at-home rapid COVID-19 test that can confirm results using an entirely automated sm
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Bear Of The Day: Becton, Dickinson and Co (BDX)

08:50pm, Tuesday, 05'th Oct 2021
Despite a beating the number in the most recent report, this stock has fallen to the lowest Zacks Rank
Thomas Polen, Becton Dickenson CEO, joins Closing Bell to talk about his company's smartphone Covid test.
On Thursday, President Joe Biden revealed his new COVID-19 action plan, which includes $2 billion in government spending on 280 million rapid point of care and at-home COVID-19 tests. On Friday, Bank
Becton, Dickinson And Company: One Of The Best Dividend SWANs You Can Buy Today
James Lim, Executive Vice President at Becton, Dickinson (NYSE:BDX), made a large buy and sell of company shares on September 3, according to a new SEC filing. What Happened: A Form 4 filing from the
EUA for BD's (BDX) At-Home COVID-19 test is expected to boost home testing to prevent outbreaks and limit the rise in COVID-19 cases from the Delta variant.
Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and regulatory approvals.
The FDA has issued an Emergency Use Authorization (EUA) for Becton Dickinson and Co's (NYSE: BDX) BD Veritor At-Home COVID-19 Test. Also Read:   BD's Automated Molecular Diagnostics Platform Wins
Becton Dickinson and Co (NYSE: BDX) has received FDA approval for its automated, sample-to-answer, high-throughput BD Cor system along with the BD Onclarity HPV Assay for extended genotyping of hum
JPMorgan downgraded Becton Dickinson and Co (NYSE:BDX) to Neutral from Overweight with a price target of $265, down from $280.  While Becton reported better than expected top and bottom-line Q3
Becton Dickinson and Company (BDX) CEO Tom Polen on Q3 2021 Results - Earnings Call Transcript
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE